房颤患者直接口服抗凝药依从性与持续性的群体研究
结果显示所有OAC的依从性为55.2%,持续性为65.9%,且不同药物间存在差异,依从性和持续性随时间在个体和系统层面均下降,合并症增多与风险降低相关。
要点
- 房颤患者OAC的1年依从性仅55.2%,持续性65.9%。
- 达比加群、利伐沙班和阿哌沙班的依从性和持续性存在差异。
- 合并症越多,非依从和非持续风险越低。
核心结论
- OAC在房颤患者中的1年依从性和持续性均较低,且因药物和时间而异。
主要发现
- 所有OAC的依从性为55.2%(95%CI 54.6-55.7),持续性为65.9%(95%CI 65.4-66.5)。
- VKA依从性51.2%(95%CI 50.6-51.8),持续性63.4%(95%CI 62.8-64.0)。
- 达比加群依从性66.5%(95%CI 63.7-69.2),持续性61.4%(95%CI 58.3-64.2)。
- 利伐沙班依从性63.1%(95%CI 61.8-64.4),持续性72.3%(95%CI 70.9-73.7)。
- 阿哌沙班依从性64.7%(95%CI 63.2-66.1),持续性78.7%(95%CI 77.1-80.1)。
临床怎么用
- 临床应关注房颤患者OAC的依从性和持续性,尤其在不同药物间存在差异。
- 合并症较多的患者非依从和非持续风险较低,但仍需个体化干预。
局限性
- 研究基于电子健康记录,可能受数据完整性影响。
- 未明确报告影响依从性和持续性的具体干预措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite simpler regimens than vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF), adherence (taking drugs as prescribed) and persistence (continuation of drugs) to direct oral anticoagulants are suboptimal, yet understudied in electronic health records (EHRs). OBJECTIVE: We investigated (1) time trends at individual and system levels, and (2) the risk factors for and associations between adherence and persistence. METHODS: In UK primary care EHR (The Health Information Network 2011-2016), we investigated adherence and persistence at 1 year for oral anticoagulants (OACs) in adults with incident AF. Baseline characteristics were analysed by OAC and adherence/persistence status. Risk factors for non-adherence and non-persistence were assessed using Cox and logistic regression. Patterns of adherence and persistence were analysed. RESULTS: Among 36 652 individuals with incident AF, cardiovascular comorbidities (median CHA2DS2VASc[Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65-74 years, Sex category] 3) and polypharmacy (median number of drugs 6) were common. Adherence was 55.2% (95% CI 54.6 to 55.7), 51.2% (95% CI 50.6 to 51.8), 66.5% (95% CI 63.7 to 69.2), 63.1% (95% CI 61.8 to 64.4) and 64.7% (95% CI 63.2 to 66.1) for all OACs, VKA, dabigatran, rivaroxaban and apixaban. One-year persistence was 65.9% (95% CI 65.4 to 66.5), 63.4% (95% CI 62.8 to 64.0), 61.4% (95% CI 58.3 to 64.2), 72.3% (95% CI 70.9 to 73.7) and 78.7% (95% CI 77.1 to 80.1) for all OACs, VKA, dabigatran, rivaroxaban and apixaban. Risk of non-adherence and non-persistence increased over time at individual and system levels. Increasing comorbidity was associated with reduced risk of non-adherence and non-persistence across all OACs. Overall rates of 'primary non-adherence' (stopping after first prescription), 'non-adherent non-persistence' and 'persistent adherence' were 3.5%, 26.5% and 40.2%, differing across OACs. CONCLUSIONS: Adherence and persistence to OACs are low at 1 year with heterogeneity across drugs and over time at individual and system levels. Better understanding of contributory factors will inform interventions to improve adherence and persistence across OACs in individuals and populations.
引用
- Banerjee A, Benedetto V, Gichuru P, et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart. 2019. PMID: 31601729. doi:10.1136/heartjnl-2019-315307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。